Jeremy Franklin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeremy Franklin has a total of 632 co-authors. Here are the top co-authors by number of shared publications:
Volker Diehl
The German Hodgkin Study Group, and
19 shared publicationsAndreas Engert
First Department of Internal Medicine and German Hodgkin Study Group (GHSG), University Hospital Cologne, Germany
18 shared publicationsV. Diehl
Klinik 1 für Innere Medizin, University Hospital of Cologne, German Hodgkin Study Group, Cologne, Germany
13 shared publications- Christopher Baethge
Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Cologne, Cologne, Germany
12 shared publications H. Tesch
Department of Internal Medicine, Klinikum der Stadt Villingen-Schwenningen, Germany
7 shared publicationsMarkus Sieber
6 shared publications
Latest Publications
- Open Access
- 31 July 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (11) , 782.e1-782.e7
Desiccating Stress Significantly Increases the Risk for Chronic Ocular Graft-versus-Host-Disease
- 31 July 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (11) , 782.e1-782.e7
Open AccessDesiccating Stress Significantly Increases the Risk for Chronic Ocular Graft-versus-Host-Disease
- Open Access
- 24 January 2022
- Published by S. Karger AG in Digestive Diseases
- Vol. 40 (6) , 826-834
Comparison of Pre-Endoscopic C-WATCH Score with Established Risk Assessment Tools in Patients with Upper Gastrointestinal Bleeding
Introduction: Use of risk scores for early assessment of patients with upper gastrointestinal bleeding (UGIB) is recommended by various guidelines. We compared Cologne-WATCH (C-WATCH) score with Glasgow-Blatchford score (GBS), Rockall score (RS), and pre-endoscopic RS (p-RS). Methods: Patients with UGIB between January and December 2017 were retrospectively analyzed for 30-day mortality and composite endpoints risk of complications and need for intervention using areas under the receiver-operating characteristics curve (AUROC). Subgroup analysis was conducted for patients with UGIB on admission and in-hospital UGIB. Results: A total of 252 patients were identified (67.5% men, mean age 63.8 ± 14.9 years). In-hospital UGIB occurred in 49.6%. AUROCs for 30-day mortality, risk of complications, and need for intervention (not applicable to RS) were 0.684 (95% confidence interval [CI]: 0.606–0.763), 0.665 (95% CI: 0.594–0.735), and 0.694 (95% CI: 0.612–0.775) for C-WATCH score, 0.724 (95% CI: 0.653–0.796) and 0.751 (95% CI: 0.687–0.815) for RS, 0.652 (95% CI: 0.57–0.735), 0.653 (95% CI: 0.579–0.727), and 0.673 (95% CI: 0.602–0.745) for p-RS and 0.652 (95% CI: 0.572–0.732), 0.663 (95% CI: 0.592–0.734), and 0.752 (95% CI: 0.683–0.821) for GBS. RS outperformed pre-endoscopic scores in predicting risk of complications, while there were no significant differences between pre-endoscopic scores except GBS outperforming p-RS in predicting need for intervention. The subgroup analysis obtained similar results. Positive predictive values for patients with estimated low risk for all three endpoints (C-WATCH score ≤1, RS ≤2, p-RS <1, and GBS ≤1) were 89%, 69%, 78%, and 92%. Conclusion: C-WATCH score performed similar to the established pre-endoscopic risk scores in patients with UGIB regarding relevant patient-related endpoints with no significant differences between both the subgroups.
- 24 January 2022
- Published by S. Karger AG in Digestive Diseases
- Vol. 40 (6) , 826-834
Open AccessComparison of Pre-Endoscopic C-WATCH Score with Established Risk Assessment Tools in Patients with Upper Gastrointestinal Bleeding
Introduction: Use of risk scores for early assessment of patients with upper gastrointestinal bleeding (UGIB) is recommended by various guidelines. We compared Cologne-WATCH (C-WATCH) score with Glasgow-Blatchford score (GBS), Rockall score (RS), and pre-endoscopic RS (p-RS). Methods: Patients with UGIB between January and December 2017 were retrospectively analyzed for 30-day mortality and composite endpoints risk of complications and need for intervention using areas under the receiver-operating characteristics curve (AUROC). Subgroup analysis was conducted for patients with UGIB on admission and in-hospital UGIB. Results: A total of 252 patients were identified (67.5% men, mean age 63.8 ± 14.9 years). In-hospital UGIB occurred in 49.6%. AUROCs for 30-day mortality, risk of complications, and need for intervention (not applicable to RS) were 0.684 (95% confidence interval [CI]: 0.606–0.763), 0.665 (95% CI: 0.594–0.735), and 0.694 (95% CI: 0.612–0.775) for C-WATCH score, 0.724 (95% CI: 0.653–0.796) and 0.751 (95% CI: 0.687–0.815) for RS, 0.652 (95% CI: 0.57–0.735), 0.653 (95% CI: 0.579–0.727), and 0.673 (95% CI: 0.602–0.745) for p-RS and 0.652 (95% CI: 0.572–0.732), 0.663 (95% CI: 0.592–0.734), and 0.752 (95% CI: 0.683–0.821) for GBS. RS outperformed pre-endoscopic scores in predicting risk of complications, while there were no significant differences between pre-endoscopic scores except GBS outperforming p-RS in predicting need for intervention. The subgroup analysis obtained similar results. Positive predictive values for patients with estimated low risk for all three endpoints (C-WATCH score ≤1, RS ≤2, p-RS <1, and GBS ≤1) were 89%, 69%, 78%, and 92%. Conclusion: C-WATCH score performed similar to the established pre-endoscopic risk scores in patients with UGIB regarding relevant patient-related endpoints with no significant differences between both the subgroups.
- 1 July 2019
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (7) , 1266-1276
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
- 1 July 2019
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (7) , 1266-1276
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
- 14 May 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (20) , 975-976
Author response: DBS of the PSA and the VIM in essential tremor: A randomized, double-blind, crossover trial
We thank Prof. Sidiropoulos for commenting on our article.1 Indeed, other studies targeted the posterior subthalamic area (PSA) more ventrally, and there might exist a certain degree of current spread from the ventral intermediate nucleus of the thalamus (VIM) into the PSA and vice versa, especially at higher amplitudes. However, we2 and others3 implanted contacts at similar z coordinates before.
- 14 May 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (20) , 975-976
Author response: DBS of the PSA and the VIM in essential tremor: A randomized, double-blind, crossover trial
We thank Prof. Sidiropoulos for commenting on our article.1 Indeed, other studies targeted the posterior subthalamic area (PSA) more ventrally, and there might exist a certain degree of current spread from the ventral intermediate nucleus of the thalamus (VIM) into the PSA and vice versa, especially at higher amplitudes. However, we2 and others3 implanted contacts at similar z coordinates before.
- 1 January 2019
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 36 (1) , 55-63
Incidence of peri-operative paediatric cardiac arrest and the influence of a specialised paediatric anaesthesia team
BACKGROUND Peri-operative critical events are still a major problem in paediatric anaesthesia care. Access to more experienced healthcare teams might reduce the adverse event rate and improve outcomes. OBJECTIVE The current study analysed incidences of peri-operative paediatric cardiac arrest before and after implementation of a specialised paediatric anaesthesia team and training programme. DESIGN Retrospective cohort study with before-and-after analysis. SETTING Department of Anaesthesiology and Intensive Care Medicine, University Hospital of Cologne, Germany. PATIENTS A total of 36 243 paediatric anaesthetics (0 to 18 years) were administered between 2008 and 2016. INTERVENTION Implementation of a specialised paediatric anaesthesia team and training programme occurred in 2014 This included hands-on supervised training in all fields of paediatric anaesthesia, double staffing for critical paediatric cases and a 24/7 emergency team. A logistic regression analysis with risk factors (age, ASA physical status, emergency) was used to evaluate the impact of implementation of the specialised paediatric anaesthesia team. MAIN OUTCOME MEASURES Incidences of peri-operative paediatric cardiac arrest and anaesthesia-attributable cardiac arrest before and after the intervention. RESULTS Twelve of 25 paediatric cardiac arrests were classified as anaesthesia-attributable. The incidence of overall peri-operative paediatric cardiac arrest was 8.1/10 000 (95% CI 5.2 to 12.7) in the period 2008 to 2013 and decreased to 4.6/10 000 (95% CI 2.1 to 10.2) in 2014 to 2016. Likewise, the incidence of anaesthesia-attributable cardiac arrest was lower after 2013 [1.6/10 000 (95% CI 0.3 to 5.7) vs. 4.3/10 000 (95% CI 2.3 to 7.9)]. Using logistic regression, children anaesthetised after 2013 had nearly a 70% lower probability of anaesthesia-attributable cardiac arrest (odds ratio 0.306, 95% CI 0.067 to 1.397; P = 0.1263). For anaesthesia-attributable cardiac arrest, young age was the most contributory risk factor, whereas in overall paediatric cardiac arrest, ASA physical statuses 3 to 5 played a more important role. CONCLUSION In this study on incidences of peri-operative paediatric cardiac arrest from a European tertiary care university hospital, implementation of a specialised paediatric anaesthesia team and training programme was associated with lower incidences of peri-operative paediatric cardiac arrest and a reduced probability of anaesthesia-attributable cardiac arrest.
- 1 January 2019
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 36 (1) , 55-63
Incidence of peri-operative paediatric cardiac arrest and the influence of a specialised paediatric anaesthesia team
BACKGROUND Peri-operative critical events are still a major problem in paediatric anaesthesia care. Access to more experienced healthcare teams might reduce the adverse event rate and improve outcomes. OBJECTIVE The current study analysed incidences of peri-operative paediatric cardiac arrest before and after implementation of a specialised paediatric anaesthesia team and training programme. DESIGN Retrospective cohort study with before-and-after analysis. SETTING Department of Anaesthesiology and Intensive Care Medicine, University Hospital of Cologne, Germany. PATIENTS A total of 36 243 paediatric anaesthetics (0 to 18 years) were administered between 2008 and 2016. INTERVENTION Implementation of a specialised paediatric anaesthesia team and training programme occurred in 2014 This included hands-on supervised training in all fields of paediatric anaesthesia, double staffing for critical paediatric cases and a 24/7 emergency team. A logistic regression analysis with risk factors (age, ASA physical status, emergency) was used to evaluate the impact of implementation of the specialised paediatric anaesthesia team. MAIN OUTCOME MEASURES Incidences of peri-operative paediatric cardiac arrest and anaesthesia-attributable cardiac arrest before and after the intervention. RESULTS Twelve of 25 paediatric cardiac arrests were classified as anaesthesia-attributable. The incidence of overall peri-operative paediatric cardiac arrest was 8.1/10 000 (95% CI 5.2 to 12.7) in the period 2008 to 2013 and decreased to 4.6/10 000 (95% CI 2.1 to 10.2) in 2014 to 2016. Likewise, the incidence of anaesthesia-attributable cardiac arrest was lower after 2013 [1.6/10 000 (95% CI 0.3 to 5.7) vs. 4.3/10 000 (95% CI 2.3 to 7.9)]. Using logistic regression, children anaesthetised after 2013 had nearly a 70% lower probability of anaesthesia-attributable cardiac arrest (odds ratio 0.306, 95% CI 0.067 to 1.397; P = 0.1263). For anaesthesia-attributable cardiac arrest, young age was the most contributory risk factor, whereas in overall paediatric cardiac arrest, ASA physical statuses 3 to 5 played a more important role. CONCLUSION In this study on incidences of peri-operative paediatric cardiac arrest from a European tertiary care university hospital, implementation of a specialised paediatric anaesthesia team and training programme was associated with lower incidences of peri-operative paediatric cardiac arrest and a reduced probability of anaesthesia-attributable cardiac arrest.
- 1 September 2018
- Published by Elsevier in World Neurosurgery
- Vol. 117, e228-e237
Posterior Lumbar Interbody Fusion versus Dynamic Hybrid Instrumentation: A Prospective Randomized Clinical Trial
- 1 September 2018
- Published by Elsevier in World Neurosurgery
- Vol. 117, e228-e237
Posterior Lumbar Interbody Fusion versus Dynamic Hybrid Instrumentation: A Prospective Randomized Clinical Trial
- 7 August 2018
- Published by Wolters Kluwer Health in Neurology
- Vol. 91 (6) , E543-E550
DBS of the PSA and the VIM in essential tremor
Objective To evaluate deep brain stimulation (DBS) of the posterior subthalamic area (PSA) in essential tremor (ET) and compare it to the ventral intermediate nucleus of the thalamus (VIM) in terms of stimulation efficacy, efficiency, and side effects. Methods DBS leads were implanted such that contacts were placed in the VIM, on the intercommissural line, and in the PSA. Thirteen patients with ET entered a randomized, double-blind crossover phase and completed a 1-year follow-up. Results PSA-DBS significantly reduced tremor severity and improved quality of life. There were no relevant differences in quality and frequency of stimulation side effects between VIM and PSA, with a tendency toward greater tremor improvement with PSA stimulation. Clinical benefit was achieved at significantly lower stimulation amplitudes in the PSA. The majority of patients remained with PSA-DBS after 1 year. Conclusion In accordance with previous retrospective investigations, our prospective data suggest that PSA-DBS is at least equally effective as but possibly more efficient than VIM-DBS. Classification of evidence This study provides Class I evidence that for patients with essential tremor, PSA-DBS is not significantly different from VIM-DBS in suppressing tremor, but clinical benefit from PSA-DBS is attained at lower stimulation amplitudes.
- 7 August 2018
- Published by Wolters Kluwer Health in Neurology
- Vol. 91 (6) , E543-E550
DBS of the PSA and the VIM in essential tremor
Objective To evaluate deep brain stimulation (DBS) of the posterior subthalamic area (PSA) in essential tremor (ET) and compare it to the ventral intermediate nucleus of the thalamus (VIM) in terms of stimulation efficacy, efficiency, and side effects. Methods DBS leads were implanted such that contacts were placed in the VIM, on the intercommissural line, and in the PSA. Thirteen patients with ET entered a randomized, double-blind crossover phase and completed a 1-year follow-up. Results PSA-DBS significantly reduced tremor severity and improved quality of life. There were no relevant differences in quality and frequency of stimulation side effects between VIM and PSA, with a tendency toward greater tremor improvement with PSA stimulation. Clinical benefit was achieved at significantly lower stimulation amplitudes in the PSA. The majority of patients remained with PSA-DBS after 1 year. Conclusion In accordance with previous retrospective investigations, our prospective data suggest that PSA-DBS is at least equally effective as but possibly more efficient than VIM-DBS. Classification of evidence This study provides Class I evidence that for patients with essential tremor, PSA-DBS is not significantly different from VIM-DBS in suppressing tremor, but clinical benefit from PSA-DBS is attained at lower stimulation amplitudes.
- 27 June 2018
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 79 (3)
Dose Increase Versus Unchanged Continuation of Antidepressants After Initial Antidepressant Treatment Failure in Patients With Major Depressive Disorder
To evaluate the efficacy and tolerability of dose increase compared to dose continuation of the initially prescribed antidepressant in antidepressant treatment failure (ATF). We searched CENTRAL, PubMed, Embase, and PsycINFO using generic terms for depression, dose increase, and randomized controlled trials (RCTs), without date or language restrictions. Of 1,780 studies screened, 9 studies reporting on 1,273 patients were included for meta-analysis (PROSPERO Registration: CRD42017058389). Studies met the following predetermined inclusion criteria: randomized controlled trial, patients diagnosed with unipolar depression according to a standardized diagnostic instrument, ATF after a standard antidepressant trial (duration of ≥ 3 weeks at a standard dose), dose increase regimen, and control group of dose continuation. Two authors extracted data independently according to the Cochrane Handbook for Systematic Reviews. Analyses are based on random effects models. All studies reported on selective serotonin reuptake inhibitors (SSRIs); 1 study also reported on maprotiline. Meta-analyses resulted in a statistically nonsignificant summary effect size of 0.053 standardized mean difference (95% CI, -0.143 to 0.248) in favor of antidepressant dose increase. Subgroup and sensitivity analyses and secondary outcome analyses resulted in similar effect estimates and supported the robustness of the results. With clinically and statistically nonsignificant effect estimates, there is evidence from RCTs against increasing the dose of SSRIs (with the possible exception of citalopram) in adult patients with major depression and ATF. Dose increase with other antidepressants (eg, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors) and in other patient groups (minor depression, children and adolescents) or after long periods of first-line antidepressant therapy (ie, 8 weeks) have not been or not been sufficiently studied and, at this time, cannot be recommended in clinical practice.
- 27 June 2018
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 79 (3)
Dose Increase Versus Unchanged Continuation of Antidepressants After Initial Antidepressant Treatment Failure in Patients With Major Depressive Disorder
To evaluate the efficacy and tolerability of dose increase compared to dose continuation of the initially prescribed antidepressant in antidepressant treatment failure (ATF). We searched CENTRAL, PubMed, Embase, and PsycINFO using generic terms for depression, dose increase, and randomized controlled trials (RCTs), without date or language restrictions. Of 1,780 studies screened, 9 studies reporting on 1,273 patients were included for meta-analysis (PROSPERO Registration: CRD42017058389). Studies met the following predetermined inclusion criteria: randomized controlled trial, patients diagnosed with unipolar depression according to a standardized diagnostic instrument, ATF after a standard antidepressant trial (duration of ≥ 3 weeks at a standard dose), dose increase regimen, and control group of dose continuation. Two authors extracted data independently according to the Cochrane Handbook for Systematic Reviews. Analyses are based on random effects models. All studies reported on selective serotonin reuptake inhibitors (SSRIs); 1 study also reported on maprotiline. Meta-analyses resulted in a statistically nonsignificant summary effect size of 0.053 standardized mean difference (95% CI, -0.143 to 0.248) in favor of antidepressant dose increase. Subgroup and sensitivity analyses and secondary outcome analyses resulted in similar effect estimates and supported the robustness of the results. With clinically and statistically nonsignificant effect estimates, there is evidence from RCTs against increasing the dose of SSRIs (with the possible exception of citalopram) in adult patients with major depression and ATF. Dose increase with other antidepressants (eg, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors) and in other patient groups (minor depression, children and adolescents) or after long periods of first-line antidepressant therapy (ie, 8 weeks) have not been or not been sufficiently studied and, at this time, cannot be recommended in clinical practice.
- 27 June 2018
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 79 (3)
Trajectories of Acute Antidepressant Efficacy
From The Journal of Clinical Psychiatry: After you start patients on antidepressant therapy, how long should it take for them to respond? This meta-analysis looks at existing data to estimate the probability of additional response to antidepressants after 4 weeks and up to 24 weeks in previously nonresponding patients.
- 27 June 2018
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 79 (3)
Trajectories of Acute Antidepressant Efficacy
From The Journal of Clinical Psychiatry: After you start patients on antidepressant therapy, how long should it take for them to respond? This meta-analysis looks at existing data to estimate the probability of additional response to antidepressants after 4 weeks and up to 24 weeks in previously nonresponding patients.